Phase II Trials of Alzheimer’s Drug Begins
MK-8931, a newly developed drug against the Alzheimer's disease, has begun with the Phase II trials in which the patients with the different level of disease will be given the drug to check the safety and effectiveness of the same.
The research, in its phase II, will consider the tests on 200 patients while in the next phase trials i. e. phase III, it will check the effect on 1,700 patients. The drug is reported to be the first of its kind that is moving towards the higher stages of the medical research.
If the drug succeeds in the trials, it will be available for use widely within next two to three years. It is believed to slow down the effect of brain destroying disease and even stop it. The success of research will send out waves of happiness among the people with the disease.
It is believed to bring out revolution in the world of medicines. Currently, there are over 5.4 million patients with Alzheimer's in the US and the number will soar to 16 million by 2050. The cost will then increase from current $200 billion to $1.1 trillion in 2050, as estimated. Merck & Co Inc is the company behind the new drug.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids